SCHEDULE 13G/A: Venrock Healthcare Capital Partners Group Amends Passive Stake in Praxis Precision Medicines to 6.1%
Beneficial Ownership Amendment
A group of Venrock Healthcare Capital Partners entities and individuals have filed an amended Schedule 13G, reporting a 6.1% beneficial ownership stake in Praxis Precision Medicines, Inc. as of December 31, 2024.
Summary
- The filing is Amendment No. 3 to Schedule 13G for Praxis Precision Medicines, Inc. (CUSIP: 74006W207).
- The reporting group, consisting of Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh, collectively beneficially owns 1,190,340 shares of Common Stock.
- This aggregate ownership represents 6.1% of the total outstanding Common Stock of Praxis Precision Medicines, Inc.
- The beneficial ownership includes 241,337 shares of Common Stock and warrants exercisable for up to 52,670 shares held by VHCP III.
- It also includes 24,132 shares of Common Stock and warrants exercisable for up to 5,270 shares held by VHCP Co-Investment III.
- Additionally, 724,516 shares of Common Stock and warrants exercisable for up to 142,415 shares are held by VHCP EG.
- The percentage of class is calculated based on 19,248,853 shares of Common Stock outstanding as of November 30, 2024, plus 200,355 shares issuable upon the exercise of warrants.
Sentiment
Score: 5
Explanation: Neutral. This is a routine regulatory filing (Schedule 13G/A) reporting passive ownership, with no positive or negative operational or financial news for the company.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding significant passive ownership stakes in the company.
Key Dates
| Date | Description |
|---|---|
| 2023-07-24 | Date of previous Schedule 13G filing for Power of Attorney for Nimish Shah and Bong Koh, incorporated by reference. |
| 2024-11-30 | Date of Common Stock outstanding count (19,248,853 shares) used for percentage calculation, as disclosed in the Issuer's Form S-3. |
| 2024-12-31 | Date of event which requires the filing of this statement (beneficial ownership snapshot date). |
| 2025-02-14 | Date of execution of the Joint Filing Agreement and filing of this Schedule 13G/A. |
Keywords
Praxis Precision Medicines, Venrock Healthcare Capital Partners, Schedule 13G/A, Beneficial Ownership, Common Stock, Warrants, Investment, Passive Investor, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.